glp-1 price drop Novo cuts prices 70%, but semaglutide revenue could grow in 2026 McKee's proposed FY2027 budget drops

had shown that injecting the short version of GLP-1 into rats profoundly reduced food intake

Analyst Opinion Sabyasachi Ghosh, Principal Consultant for Healthcare at FMI, suggests, The GLP-1 receptor agonist market is expected to shift toward companies able to combine clinical evidence with reliable supply execution

New diets are tried, certain foods are substituted, new supplements are taken, maybe more exercise occurs

The dual GIP/GLP-1 mechanism of tirzepatide versus semaglutide does not guarantee worse digestive effects for every individual, even though the population-level data suggests slightly higher incidence

This experience taught me how to combine the latest science with a pragmatic approach to habit change